ALEC
vs
S&P 500
ALEC
S&P 500
Over the past 12 months, ALEC has underperformed S&P 500, delivering a return of -26% compared to the S&P 500's +12% growth.
Stocks Performance
ALEC vs S&P 500
Performance Gap
ALEC vs S&P 500
Performance By Year
ALEC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Alector Inc
Glance View
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 208 full-time employees. The company went IPO on 2019-02-07. The firm is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. The firm is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. The firm has advanced four product candidates, AL001, AL002, AL003, and AL101, into clinical development. Its first product candidate, AL001, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients. Its AL002 targets triggering receptor expressed on myeloid cells 2 (TREM2) to increase the functionality of TREM2 signaling and enhance microglia cell activation.
